Apolipoprotein B metabolism in humans: Studies with stable isotope-labeled amino acid precursors

Atherosclerosis

Volumn 162, Issue 2, 2002, Pages 227-244

  Marsh, Julian B ^a   Welty, Francine K ^a   Lichtenstein, Alice H ^a   Lamon Fava, Stefania ^a   Schaefer, Ernst J ^a  

^a TUFTS UNIVERSITY   (United States)

Author keywords

ApoB100 and apoB48; Hereditary dyslipidemias; Hormonal perturbations; Nephrotic syndrome; Statins

Indexed keywords

APOLIPOPROTEIN B; APOLIPOPROTEIN E; CHOLESTEROL ESTER; ESTROGEN; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; LIPOPROTEIN LIPASE; OMEGA 3 FATTY ACID; STABLE ISOTOPE; VERY LOW DENSITY LIPOPROTEIN;

AGING; CHOLESTEROL ESTER STORAGE DISEASE; CHOLESTEROL SYNTHESIS; DIABETES MELLITUS; DYSLIPIDEMIA; ENZYME ACTIVITY; FAMILIAL HYPERCHOLESTEROLEMIA; FAT INTAKE; HUMAN; HYPERLIPIDEMIA; HYPERLIPOPROTEINEMIA TYPE 1; HYPOBETALIPOPROTEINEMIA; ISOTOPE LABELING; LIPOPROTEIN METABOLISM; MASS SPECTROMETRY; METHODOLOGY; NEPHROTIC SYNDROME; PRIORITY JOURNAL; REVIEW;

AMINO ACIDS; APOLIPOPROTEINS B; GENETIC DISEASES, INBORN; HORMONES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; ISOTOPES; NEPHROTIC SYNDROME; PROTEIN PRECURSORS; REFERENCE VALUES;

EID: 0036233672     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(01)00709-2     Document Type: Review

References (118)

1. Cardiovascular disease and hyperlipidaemia
2. Triglyceride lipases and atherosclerosis
3. The mammalian low-density lipoprotein receptor family
4. A macrophage receptor for apolipoprotein B48: Cloning, expression, and atherosclerosis
5. Direct measurement of apolipoprotein B synthesis in human VLDL using stable isotopes and mass spectrometry
6. Apolipoprotein metabolism: A stable-isotope approach
7. New in-vivo techniques for measuring lipoprotein metabolism
8. Sensitive methods to study human apolipoprotein B metabolism using isotope-labeled amino acids
9. Kinetic study of apo B100-containing lipoprotein metabolism using amino acids labeled with stable isotopes: Methodological aspects
10. Stable isotope turnover of apolipoproteins of high-density lipoproteins in humans
11. Comparison of deuterated leucine, valine, and lysine in the measurement of human apolipoprotein A-I and B-100 kinetics
12. Measurement of very low density and low density lipoprotein apolipoprotein B-100 and high density lipoprotein apo A-I production in human subjects using deuterated leucine
13. 15N]glycine in the measurement of apolipoprotein B synthesis in perfused rat liver
14. A study of the metabolism of apolipoprotein B100 in relation to insulin resistance in African American males
15. Isopropanol precipitation method for the determination of apolipoprotein B specific activity and plasma concentrations during metabolic studies of VLDL and LDL apolipoprotein B
16. Use of gas chromatography-combustion-isotope ratio mass spectrometry in nutrition and metabolic research
17. Long-term kinetic study of B-carotene, using accelerator mass spectrometry in an adult volunteer
18. Apoproteins of the lipoproteins in a nonrecirculating perfusate of rat liver
19. Estimating the fractional synthetic rate of plasma apolipoproteins and lipids from stable isotope data
20. Models to interpret kinetic data in stable isotope tracer studies
21. Kinetics of very-low-density lipoprotein apolipoprotein B-100 in normolipidemic subjects: Pooled analysis of stable-isotope studies
22. Incorporation of 15N-glycine into VLDL and LDL: In vivo synthesis of apolipoprotein B in post-absorptive and fasting individuals
23. Nutritional regulation of cholesterol synthesis and apolipoprotein B kinetics: Studies in patients with familial hypercholesterolemia and normal subjects treated with a high carbohydrate, low fat diet
24. Metabolism of apolipoprotein B-100 and of triglyceride-rich lipoprotein particles in the absence of functional lipoprotein lipase
25. Effects of fish oil supplementation on apolipoprotein B 100 production and lipoprotein metabolism in normolipidaemic males
26. Fish consumption decreases TRL apo B48 and apo B100 production rates
27. Suppression by diets rich in fish oil of very low density lipoprotein production in man
28. Impact of age on the metabolism of VLDL, IDL, and LDL apolipoprotein B-100 in men
29. Influence of age on the metabolism of plasma low density lipoproteins in healthy males
30. Human apolipoprotein (apo) B-48 and apoB-100 kinetics with stable isotopes
31. Regulation of apo B secretion from HepG2 cells: Evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge
32. Cholesterol is required for the secretion of the very-low-density lipoprotein: In vivo studies
33. Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B-containing lipoprotein from HepG2 cells by cholesteryl ester
34. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B-100 in normolipidemic subjects
35. Direct association between the hepatic secretion of VLDL apolipoprotein B-100 and plasma mevalonic acid and lathosterol concentrations in man
36. Inhibition of cholesterogenesis decreases hepatic secretion of apoB-100 in normolipidemic subjects
37. Resistance to diet-induced hypercholesterolemia and gallstone formation in ACAT2-deficient mice
38. Insights into apolipoprotein B biology from transgenic and gene-targeted mice
39. Slower removal of intestinal apolipoprotein B-48 than of apolipoprotein B-100 in severely hypertriglyceridemic subjects
40. Slower catabolism of apo B-48 in triglyceride-rich lipoproteins during heparin infusions in Type 5 hyperlipoproteinemic subjects
41. Metabolism of apolipoprotein B-48 and B-100 of triglyceride-rich lipoproteins in patients with familial dysbetalipoproteinemia
42. 3]leucine
43. Effects of ApoE genotype on ApoB-48 and ApoB-100 kinetics with stable isotopes in humans
44. Increased hepatic secretion of VLDL apoB100 in cholesteryl ester storage disease
45. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin. Implications for regulation of apoilipoprotein B synthesis
46. Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency
47. Familial hypobetalipoproteinemia
48. Lipoproteins containing the truncated apolipoprotein, Apo B-89, are cleared from human plasma more rapidly than Apo B-100-containing lipoproteins in vivo
49. Hompzygous familial hypobetalipoproteinemia: Increased LDL catabolism in hypobetalipoproteinemia due to a truncated apolipoprotein B species, apo B-87-Padova
50. ApoB-75, a truncation of apolipoprotein B associated with familial hypobetalipoproteinemia: Genetic and kinetic studies
51. Dysbetalipoproteinemia in a kindred with hypobetalipoproteinemia due to mutations in the genes for apo B (Apo B-70.5) and apo E ( Apo E2)
52. Decreased production and increased catabolism of apolipoprotein B-100 in apolipoprotein B-67/B-100 heterozygotes
53. Lipoproteins containing the truncated apolipoprotein, Apo B-89, are cleared from human plasma more rapidly than Apo B-100-containing lipoproteins in vivo
54. Positive linear correlation between the length of truncated apolipoprotein B and its secretion rate: In vivo studies in human apo B-89, apo B-75, apo B-54.8 and apo B-31 heterozygotes
55. Production of apolipoprotein B-67 in apolipoprotein B-67/B-100 heterozygotes: Technical problems associated with leucine contamination in stable isotope studies
56. Molecular and metabolic basis for the metabolic disorder normotriglyceridemic abetalipoproteinemia
57. Apoprotein B-100 production is decreased in subjects heterozygous for truncations of apoprotein B
58. Metabolism of apolipoprotein B-100 in a kindred with familial hypobetalipoproteinemia without a truncated form of apoB
59. Metabolic studies in familial hypercholesterolemia: Evidence for a gene-dosage effect in vivo
60. Increased hepatic secretion of VLDL apolipoprotein B-100 in heterozygous familial hypercholesterolemia: A stable isotope study
61. VLDL and IDL apolipoprotein B-100 kinetics in familial hypercholesterolemia due to impaired LDL receptor function or to defective apolipoprotein B-100
62. 3H]leucine tracer
63. Familial combined hyperlipidaemia: Use of stable isotopes to demonstrate overproduction of very low-density lipoprotein apolipoprotein B by the liver
64. The effect of lovastatin on very low-density lipoprotein apolipoprotein B production by the liver in familial combined hyperlipidaemia
65. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidemia
66. A familial combined hyperlipidemic kindrer with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy
67. The molecular mechanism for the genetic disorder Familial Defective Apolipoprotein B100
68. Increased clearance of low density lipoprotein precursors in patients with heterozygous familial defective apolipoprotein B-100: A stable isotope approach
69. Homozygous familial defective apolipoprotein B-100 - Enhanced removal of apolipoprotein E-containing VLDLs and decreased production of LDLs
70. Lipoprotein, apolipoprotein, and lipolytic enzyme changes following estrogen administration in postmenopausal women
71. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial
72. Effects of low dose oral contraceptives on very low density and low density lipoprotein metabolism
73. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females
74. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins
75. Comparison of transdermal estradiol and oral estrogen-progestin replacement therapy effects on serum lipids and lipoproteins
76. Effect of estrogen on very low density lipoprotein and low density lipoprotein subclass metabolism in postmenopausal women
77. Estrogen treatment and human lipoprotein metabolism
78. Hepatic cholesterol metabolism in estrogen-treated men
79. Lipoproteins, apolipoproteins, and low density lipoproteins particle size among diabetics in the Framingham Offspring Study
80. The severity of coronary atherosclerosis in type 2 diabetes mellitus is related to the number of circulating triglyceride-rich lipoprotein particles
81. Increased hepatic secretion of VLDL apoB100 in NIDDM
82. Insulin regulates apolipoprotein turnover and phosphorylation in rat hepatocytes
83. Metabolic abnormalities of apolipoprotein B-containing lipoproteins in non-insulin-dependent diabetes: A stable isotope kinetic study
84. Acute hyperinsulinemia decreases the hepatic secretion of VLDL apoB100 in NIDDM
85. Metabolic basis of hypotriglyceridemic effects of insulin in normal men
86. Glycosylation of low density lipoproteins to an extent seen in diabetes slows their catabolism
87. Regulation of low density lipoprotein receptor mRNA by insulin in human hepatoma HepG2 cells
88. Impact of body mass index on coronary heart disease risk factors in men and women - The Framingham Offspring Study
89. Body weight and mortality among women
90. Increased hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in obesity: A stable isotope study
91. Regulation of the production and catabolism of plasma low density lipoproteins in hypertriglyceridemic subjects. Effect of weight loss
92. Integrated regulation of very low density lipoprotein triglyceride and apolipoprotein B kinetics in man: Normolipemic subjects, familial hypertriglyceridemia and familial combined hyperlipidemia
93. Influence of obesity on the metabolism of apolipoprotein B in humans
94. Very low density lipoprotein overproduction in genetic forms of hypertriglyceridemia
95. Abnormalities of very low density lipoprotein apolipoprotein B-100 metabolism contribute to the dyslipidemia of adult growth hormone deficiency
96. Very-low-density lipoprotein apolipoprotein B100 kinetics in adult hypopituitarism
97. Effects of growth hormone (GH) replacement therapy on very low density lipoprotein apolipoprotein B100 kinetics in patients with adult GH deficiency: A stable isotope study
98. Effects of growth hormone treatment on very-low-density lipoprotein apolipoprotein B100 turnover in adult hypopituitarism
99. Lipoprotein metabolism in experimental nephrosis
100. Physiologic mechanisms of action of lovastatin in nephrotic syndrome
101. Increased VLDL in nephrotic patients results from a decreased catabolism while increased LDL results from increased synthesis
102. A simultaneous study of the metabolism of apolipoprotein B and albumin in nephrotic patients
103. Abnormalities of lipoprotein metabolism in patients with the nephrotic syndrome
104. Metabolism of apolipoprotein B-containing lipoproteins in subjects with nephrotic-range proteinuria
105. Metabolism of low density lipoproteins in nephrotic dyslipidemia: Comparison of hypercholesterolemia alone and combined hyperlipidemia
106. Lipoprotein kinetics in patients with analbuminemia. Evidence for the role of serum albumin in controlling lipoprotein metabolism
107. Proteinuria, not altered albumin metabolism, affects hyperlipidemia in the nephrotic rat
108. Effect of simvastatin on receptor-dependent low density lipoprotein catabolism in normocholesterolemic human volunteers
109. Effect of pravastatin on metabolic parameters of apolipoprotein B in patients with mixed hyperlipoproteinemia
110. Lovastatin decreases de novo cholesterol synthesis and LDL apo B-100 production rates in combined-hyperlipidemic males
111. A familial combined hyperlipidemic kindrer with impaired apolipoprotein B catabolism. Kinetics of apolipoprotein B during placebo and pravastatin therapy
112. Simvastatin decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in heterozygous familial hypercholesterolaemia: Pathophysiological and therapeutic implications
113. Clinical pharmacology of the hypocholesterolemic agent K 12.148 (lifibrol) in healthy volunteers
114. Lifibrol enhances the LDL apolipoprotein B-100 turnover in patients with hypercholesterolemia and mixed hyperlipidemia
115. The unstirred water layer as a site of control of apolipoprotein B secretion
116. Effect of heparin-stimulated plasma lipolytic activity on VLDL apo B subclass metabolism in normal subjects
117. Metabolic basis of hypotriglyceridemi effects of insulin in normal men
118. A minimal model using stable isotopes to study the metabolism of apolipoprotein B-containing lipoproteins in humans